Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: In vitro characteristics and in vivo evaluation

International Journal of Pharmaceutics

Volumn 422, Issue 1-2, 2012, Pages 151-159

  Rabišková, Miloslava ^a   Bautzová, Tereza ^a,b   Gajdziok, Jan ^a   Dvořáčková, Kateřina ^a   Lamprecht, Alf ^b   Pellequer, Yann ^b   Spilková, Jiřina ^c  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Chitosan; Coated pellets; Colonic delivery; In vitro characteristics; In vivo evaluation; Rutin

Indexed keywords

ALGINIC ACID; BETA GLUCOSIDASE; BUFFER; CAFFEIC ACID; CHITOSAN; HYDROXYPROPYLMETHYLCELLULOSE; MYELOPEROXIDASE; RUTOSIDE; ZINC ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PELLET; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; ENZYME ACTIVITY; FECES; GASTROINTESTINAL TRACT; HEALING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PELLET EXTRUSION; PH; PRIORITY JOURNAL; RAT; RECTUM HEMORRHAGE; SPHERONIZATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ALGINATES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUFFERS; CAFFEIC ACIDS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COLITIS; COLON; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; DRUG IMPLANTS; DRUG STABILITY; GASTROINTESTINAL AGENTS; GLUCURONIC ACID; HEXURONIC ACIDS; HYDROGEN-ION CONCENTRATION; MALE; METHYLCELLULOSE; RATS; RATS, WISTAR; RUTIN; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; TRINITROBENZENESULFONIC ACID; ZINC ACETATE;

EID: 84655163812     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.10.045     Document Type: Article

References (44)

1. D.C. Baumgart, and W.J. Sandborn Inflammatory bowel disease: clinical aspects and established and evolving therapies Lancet 369 2007 1641 1657 (Pubitemid 46722637)
2. T. Bautzova, M. Rabiskova, and A. Lamprecht Multiparticulate systems containing 5-ASA for the treatment of inflammatory bowel disease Drug Dev. Ind. Pharm. 37 2011 in print
3. A. Berthold, K. Cremer, and J. Kreuter Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for anti-inflammatory drugs J. Controlled Release 39 1996 17 25 (Pubitemid 26139808)
4. G. Bresci, G. Parisi, M. Bertoni, and A. Capria Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up Dig. Liver Dis. 34 2002 419 423 (Pubitemid 34679064)
5. M.C. Chuong, J.M. Christensen, and J.W. Ayres New dissolution method for mesalamine tablets and capsules Dissolution Technol. 15 2008 7 14
6. V. Crespy, C. Morand, C. Manach, C. Besson, C. Demigne, and C. Remesy Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen Am. J. Physiol. Gastrointest. Liver Physiol. 277 1999 120 126
7. T. Cruz, J. Galvez, M.A. Ocete, M.E. Crespo, L.H.F. Sanchez de Medina, and A. Zarzuelo Oral administration of rutoside can ameliorate inflammatory bowel disease in rats Life Sci. 62 1998 687 695 (Pubitemid 28045576)
8. S. Cuzzocrea, A. Rossi, E. Mazzon, R. Di Paola, T. Genovese, C. Muia, A.P. Caputi, and L. Sautebin 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration Lab. Invest. 85 2005 808 822 (Pubitemid 40799710)
9. P.B. Deasy, and M.F.L. Law Use of extrusion-spheronization to develop an improved oral dosage form of indomethacin Int. J. Pharm. 148 1997 201 209 (Pubitemid 27160977)
10. C. Dhalleine, A. Assifaoui, B. Moulari, Y. Pellequer, P. Cayot, A. Lamprecht, and O. Chambin Zinc-pectinate beads as an in vivo self-assembling system for pulsatile drug delivery Int. J. Pharm. 414 2011 28 34
11. K. Dvorackova, G. Skrabakova, and M. Rabiskova Influence of formulation technology on theophylline release from chitosan-based pellets Ces. Slov. Farm. 58 2009 216 224
12. J. Fallingborg, L.A. Christensen, B.A. Jacobsen, and S.N. Rasmussen Very low intraluminal colonic pH in patients with active ulcerative colitis Dig. Dis. Sci. 38 1993 1989 1993 (Pubitemid 23336560)
13. P.G. Farup, T.A. Hinterleitner, M. Lukas, X. Hebuterne, D. Rachmilewitz, M. Campieri, R. Meier, R. Keller, B. Rathbone, and E. Oddsson Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis Inflamm. Bowel Dis. 7 2001 237 242 (Pubitemid 32776517)
14. C. Fiocchi Inflammatory bowel disease: current concepts of pathogenesis and implications for therapy Minerva Gastroenterol. Dietol. 48 2002 215 226 (Pubitemid 36013858)
15. J. Galvez, M. Garrido, M. Merlos, M.I. Torres, and A. Zarzuelo Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat Br. J. Pharmacol. 130 2000 1949 1959 (Pubitemid 30655808)
16. W.R. Gombotz, and S.F. Wee Protein release from alginate matrices Adv. Drug Deliv. Rev. 31 1998 267 285 (Pubitemid 28191869)
17. L. Illum Chitosan and its use as a pharmaceutical excipient Pharm. Res. 15 1998 1326 1331 (Pubitemid 28427917)
18. S. Jose, K. Dhanya, T.A. Cinu, J. Litty, and A.J. Chacko Colon targeted drug delivery: different approaches J. Young Pharmacists 1 2009 13 19
19. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity Gastroenterology 87 1984 1344 1350
20. K.H. Kwon, A. Murakami, T. Tanaka, and H. Ohigashi Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression Biochem. Pharmacol. 69 2005 395 406 (Pubitemid 40094500)
21. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Maincent, Y. Kawashima, and C.M. Lehr Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease J. Pharmacol. Exp. Ther. 299 2001 775 781
22. A. Lamprecht, H. Yamamoto, N. Ubrich, H. Takeuchi, P. Maincent, and Y. Kawashima FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression Pharm. Res. 22 2005 193 199 (Pubitemid 40487202)
23. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles J. Controlled Release 104 2005 337 346 (Pubitemid 40724934)
24. F. Magro, S. Fraga, I. Azevedo, and P. Soarez-Da-Silva Intestinal 5-hydroxytryptamine and mast cell infiltration in at experimental colitis Dig. Dis. Sci. 51 2006 495 501
25. Marcussen, J., Brandsborg, E., 2002. Enteric coating, comprising alginic acid, for an oral preparation. US Patent 6455052.
26. F.L. Mi, H.W. Sung, and S.S. Shyu Drug release from chitosan-alginate complex beads reinforced by a naturally occurring crosslinking agent Carbohydr. Polym. 48 2002 61 72
27. G.P. Morris, P.L. Beck, M.S. Herridge, W.T. Depew, M.R. Szewczuk, and J.L. Wallace Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 96 1989 795 803 (Pubitemid 19057602)
28. K. Murota, and J. Terao Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism Arch. Biochem. Biophys. 417 2003 12 17 (Pubitemid 36960043)
29. K. Na, and Y.H. Bae pH-sensitive polymers for drug delivery G.S. Kwon, Polymeric Drug Delivery Systems 2005 Taylor and Francis Boca Raton 129 180
30. K. Nemeth, and M.K. Piskula Food content, processing, absorption and metabolism of onion flavonoids Food Sci. Nutr. 47 2007 397 409 (Pubitemid 46676538)
31. S.G. Nugent, D. Kumar, D.S. Rampton, E. Yazaki, and D.F. Evans Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 2001 571 577 (Pubitemid 32234805)
32. B. Oldenburg, H. van Kats-Renaud, J.C. Koningsberger, G.P. van Berge Henegouwen, and B.S. van Asbeck Chemiluminescence in inflammatory bowel disease patients: a parameter of inflammatory activity Clin. Chim. Acta 310 2001 151 156 (Pubitemid 32728344)
33. G. Patel, R. Patel, J. Patel, P. Bharadia, and M. Patel Sodium alginate: physiological activity, usage and potential applications Drug Deliv. Technol. 7 2007 28 37
34. J.P. Perez, and M. Rabiskova Influence of the drying technique on theophylline pellets prepared by extrusion-spheronization Int. J. Pharm. 242 2002 349 351
35. N. Poelvoorde, N. Huyghebaert, C. Vervaet, and J.P. Remon Optimisation of an enteric coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis Eur. J. Pharm. Biopharm. 69 2008 969 976
36. M. Rabiskova, T. Bautzova, K. Dvorackova, and J. Spilkova Beneficial effects of rutin, quercitrin and quercetin on inflammatory bowel disease Ces. Slov. Farm. 58 2009 47 54
37. M. Rabiskova, K. Dvorackova, and L. Kofronova Stability testing of alginate-chitosan films Ces. Slov. Farm. 60 2011 in print
38. R.S. Rowe, P.J. Sheskey, and S.C. Owen Handbook of Pharmaceutical Excipients fifth ed. 2006 Pharmaceutical Press Washington
39. B.E. Sands Therapy of inflammatory bowel disease Gastroenterology 18 2000 68 82
40. J. Scala-Bertola, J. Gajdziok, M. Rabiskova, F. Bonneaux, T. Lecompte, A. Sapin, and P. Maincent Pellets for oral administration of low-molecular-weight heparin Drug Dev. Ind. Pharm. 35 2009 1503 1510
41. H. Steckel, and F. Mindermann-Nogly Production of chitosan pellets by extrusion/spheronization Eur. J. Pharm. Biopharm. 57 2004 107 114 (Pubitemid 38058809)
42. A.L. Ungell, and B. Abrahamsson Biopharmaceutical support in candidate drug selection M. Gibson, Pharmaceutical Formulation and Preformulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form 2004 Informa Healthcare New York 129 171
43. W.M. Zeng Oral controlled release formulation for highly water-soluble drugs: drug-sodium alginate-xanthan gum-zinc acetate matrix Drug Dev. Ind. Pharm. 30 2004 491 495 (Pubitemid 38821860)
44. H. Zhang, and S.H. Neau In vitro degradation of chitosan by a commercial enzyme preparation: effect of molecular weight and degree of deacetylation Biomaterials 22 2001 1653 1658 (Pubitemid 32551916)